Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Canada

Research and Innovation Action · Running

P-PEAKS UTI Personalized-Phage Against E. Coli with IV Antibiotic to Knockout Stable Biofilms in Urinary Tract Infections

Coordinator
Unity Health Toronto, Canada
Runs
1 June 2026 to 31 May 2030
Status
Running
EU funding
€15.6m
Total cost
—
Partners
20 organisations in 12 countries
Type
Research and Innovation Action
Grant agreement
101289070

What the project is doing

In the project's own words, from its summary on CORDIS.

P-PEAKS UTI is a multicenter, intercontinental Phase II randomized controlled trial evaluating the safety, efficacy, and feasibility of personalized bacteriophage therapy in combination with intravenous beta-lactam antibiotics for the secondary prevention of recurrent urinary tract infections (rUTIs) caused by Escherichia coli in female patients . The study will recruit 216 participants across 9 clinical sites, including high-risk renal transplant recipients.

Phage therapy or placebo will be administered via oral (day 1 and 2), bladder instillation (day 1), and topical/vaginal routes all over 5 days. Both arms will receive a single dose of IV antibiotic on day 2 to enhance bacterial clearance and biofilm disruption. This combination strategy leverages potential synergy between phages and antibiotics, aiming to reduce recurrence rates and antibiotic use. The project integrates AI-based phage-host prediction, GMP and Magistral phage production, and standardized susceptibility testing aligned with EUCAST guidelines.

It investigates phage immunogenicity, microbiome dynamics, and pharmacokinetics/pharmacodynamics to inform future personalized antimicrobial strategies. P-PEAKS UTI also performs health economic analysis to quantify cost-effectiveness of phage therapy in urinary tract infections compared to standard antibiotic treatment and engages patients to address stigma and acceptability of phage therapy. It contributes to regulatory science by generating quantifiable, replicable data to support future market authorization of phage therapies and informs policy through collaboration with EMA and national agencies.

In the longer term, we aim to deliver an improved, effective and meaningful solution for the prevention of recurrent UTIs in female patients improving their health outcomes and quality of life. This will also strengthen healthcare systems’ capacity to combat antimicrobial resistance and empower citizens with knowledge-based alternatives to antibiotics.

Who is involved

OrganisationCityCountryRole
Unity Health TorontoTorontoCanadaCoordinator
Europaischer NierenpatientenverbandWienAustriaParticipant
Patrimoine De L'ecole Royale Militaire - Vermogen Van De Koninklijke Militaire SchoolBruxelles / BrusselBelgiumParticipant
Qeen Biotechnologies Inc.GatineauCanadaParticipant
Universite LavalQuebecCanadaParticipant
University of CalgaryCalgary AlbertaCanadaParticipant
Philipps Universitaet MarburgMarburgGermanyParticipant
Sihtasutus Tartu Ulikooli KliinikumTartuEstoniaParticipant
Tartu UlikoolTartuEstoniaParticipant
Fundacion Publica Galega De Investigacion Biomedica InibicA CorunaSpainParticipant
Assistance Publique Hopitaux De ParisParisFranceParticipant
Hadassah Medical OrganizationJerusalemIsraelParticipant
The Hebrew University of JerusalemJerusalemIsraelParticipant
Azienda Ospedaliero Universitaria PisanaPisaItalyParticipant
Lunds UniversitetLundSwedenParticipant
Micron Research LimitedElyUnited KingdomParticipant
University College LondonLondonUnited KingdomParticipant
Baylor College of MedicineHouston TxUnited StatesParticipant
Mayo ClinicRochesterUnited StatesParticipant
The Regents of the University of CaliforniaOaklandUnited StatesParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI